Dapsone in rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 25, Issue 6, 1996, Pages 390-403

  Chang, D J ^a   Lamothe, M ^a   Stevens, R M ^a   Sigal, L H ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Dapsone; disease modifying agents; rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; DAPSONE; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE;

AGRANULOCYTOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOREGULATION; LEUKOPENIA; LIVER TOXICITY; MALE; METHEMOGLOBINEMIA; NEPHROTIC SYNDROME; NEUTROPHIL CHEMOTAXIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS;

EID: 0030007585     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(96)80004-7     Document Type: Article

References (78)

1. Lang P.G. Jr Sulfones and sulfonamides in dermatology today J Am Acad Dermatol 1 1979 479 492
2. Ileana M. Mills J. Leoung G. Oral therapy for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprimsulfamethoxazoleversus trimethoprim-dapsone N Engl J Med 323 1990 776 782
3. Podzamczer D. Salazar A. Jimenez J. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumoniaand toxoplasmosis in patients infected with HIV Ann Intern Med 122 1995 755 761
4. Katz S.I. Dermatitis herpetiformis: Clinical, histologic, therapeutic and laboratory clues Int J Dermatol 17 1978 529 535
5. Katz S.I. Treatment: drugs and diet moderator Katz S.I. Dermatitis herpetiformis: the skin and the gut Ann Intern Med 93 1980 869 871 857-874
6. Katz S.I. Commentary: sulfoxone (diasone) in the treatment of dermatitis herpetiformis Arch Dermatol 118 1982 809 812
7. Katz S.I. Gallin J.I. Hertz K.C. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone Medicine (Baltimore) 56 1977 443 455
8. Matthews C.N. Saihan E.M. Warin R.P. Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone Br J Dermatol 99 1978 455 457
9. Ruzicka T. Goerz G. Dapsone in the treatment of lupus erythematosus Br J Dermatol 104 1981 53 56
10. Holtman J.H. Neustadt D.H. Klein J. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2deficiency J Rheumatol 17 1990 1222 1225
11. Rothe M.J. Kerdel F.A. Treatment of cutaneous lupus erythematosus Lupus 1 1992 351 356
12. Callen J.P. Treatment of cutaneous lesions in patients with lupus erythematosus Dermatol Clin 12 1994 201 206
13. Highet A.S. Urticarial vasculitis resembling systemic lupus erythematosus: efficacy of prednisone and dapsone combined Br J Dermatol 102 1980 358 360
14. Fortson J.S. Zone J.J. Hammond M.E. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone J Am Acad Dermatol 15 1986 1137 1142
15. Conner B. Case for diagnosis: leukocytoclastic vasculitis Proc R Soc Med 66 1973 438 440
16. Thompson D.M. Heaf P.J. Robinsin T.W. Australia antigen polyarteritis treated with prednisone and dapsone Proc R Soc Med 69 1976 389 390
17. Asghar S.S. Westerhof W. Das P.K. Treatment of vasculitis with chlorpromazine and dapsone Arch Dermatol Res 277 1985 504 506
18. Fredenberg M.F. Malkinson F.D. Sulfone therapy in the treatment of leukocytoclastic vasculitis J Am Acad Dermatol 16 1987 772 778
19. Bernard P. Arnaud M. Treves R. Dapsone and rheumatoid vasculitis leg ulcerations J Am Acad Derm 18 1988 140 141
20. Wells G.C. Allergic vasculitis (tri-symptom of Gougerot) treated with dapsone Proc R Sac Med 62 1969 665 666
21. Ledermann J.A. Hoffbrand B.I. Dapsone in allergic vasculitis: its use in Henoch-Schonlein disease following vaccination J R Soc Med 76 1983 613 614
22. Martin J. Roenigk H.H. Lynch W. Relapsing polychondritis treated with dapsone Arch Dermatol 112 1976 1272 1274
23. Barranco V.P. Minor D.B. Solomon H. Treatment of relapsing polychondritis with dapsone Arch Dermatol 112 1976 1286 1288
24. McConkey B. Davies P. Crockson R.A. Dapsone in rheumatoid arthritis Rheumatol Rehabil 15 1976 230 234
25. McConkey B. Davies P. Crockson R.A. Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis Ann Rheum Dis 38 1979 141 144
26. Dawes P.T. Fowler P.D. Clarke S. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression Br J Rheumatol 25 1986 44 49
27. Swinson D.R. Zlosnick J. Jackson L. Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis Ann Rheum Dis 40 1981 235 239
28. Fowler P.D. Shadforth M.F. Crook P.R. Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study Ann Rheum Dis 43 1984 200 204
29. Haar D. Solvkjaer M. Unger B. A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis Scand J Rheumatol 22 1993 113 118
30. Olsen T.G. Wright R.C. Lester A.I. Subcorneal pustular dermatosis and crippling arthritis Arch Dermatol 115 1979 185 188
31. Roger H. Thevenet J.P. Souteyrand P. Subcorneal pustular dematosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvement with dapsone treatment Ann Rheum Dis 49 1990 190 191
32. Barranco V.P. Inhibition of lysosomal enzymes by dapsone Arch Dermatol 110 1974 563 566
33. Mier P.D. van den Hurk J.J.M.A. Inhibition of lysosomal enzymes by dapsone Br J Dermatol 93 1975 471 472
34. Williams K. Capstick R.B. Lewis D.A. Antiinflammatory actions of dapsone and its related biochemistry J Pharm Pharmacol 28 1976 555 558
35. Stendahl O. Molin L. Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone J Clin Invest 62 1978 214 220
36. Anderson R. Gatner E.M. van Rensburg C.E. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy Antimicrob Agents Chemother 19 1981 495 503
37. Kazmierowski J.A. Ross J.E. Peizner D.S. Dermatitis herpetiformis: effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity J Clin Immunol 4 1984 55 64
38. van Zyl J.M. Basson K. Kriegler A. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system Biochem Pharmacol 42 1991 599 608
39. Kettle A.J. Winterbourn C.C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs Biochem Pharmacol 41 1991 1485 1492
40. Niwa Y. Sakane T. Miyachi Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates-in comparison with that of colchicine and various scavengers Biochem Pharmacol 33 1984 2355 2360
41. Theron A. Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro Am Rev Respir Dis 132 1985 1049 1054
42. Martin W.J. 2d Kachel D.L. Reduction of neutrophilmediated injury to pulmonary endothelial cells by dapsone Am Rev Respir Dis 131 1985 544 547
43. Miyachi Y. Niwa Y. Effects of potassium iodide, colchicine, and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates Br J Dermatol 107 1982 209 214
44. Harvath L. Yancey K.B. Katz S.I. Selective inhibition of neutrophil chemotaxis to N-formyl-methionyl-leucylphenylalanine by sulfones J Immunol 137 1986 1305 1311
45. 4 binding and bioresponse at the cellular and physiologic levels Eur J Pharmacol 158 1988 85 89
46. Booth S.A. Moody C.E. Dahl M.V. Dapsone suppresses integrin-mediated neutrophil adherence function J Invest Dermatol 98 1992 135 140
47. Ruzicka T. Wasserman S.I. Soter N.A. Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone J Allergy Clin Immunol 72 1983 365 370
48. Katz S.I. Hertz K.C. Crawford P.S. Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions J Invest Dermatol 67 1976 688 690
49. Katz S.I. Strober W. The pathogenesis of dermatitis herpetiformis J Invest Dermatol 70 1978 63 79
50. Graham W.R. Jr Adverse effects of dapsone Int J Dermatol 14 1975 494 500
51. Coleman M.D. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance Br J Dermatol 129 1993 507 513
52. Bernstein J.E. Lorincz A.L. Sulfonamides and sulfones in dermatologic therapy Int J Dermatol 20 1981 81 88
53. Manfredi G. De Panfilis G. Zampetti M. Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage Br J Dermatol 100 1979 427 432
54. Banzato C.E. Magna L.A. In vitro effect of dapsone on NADH-methemoglobin reductase Int J Lepr Other Mycobact Dis 59 1991 486 487
55. Hornsten P. Keisu M. Wiholm B.E. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988 Arch Dermatol 126 1990 919 922
56. Ognibene A.J. Agranulocytosis due to dapsone Ann Intern Med 72 1970 521 524
57. Friman F. Nystrom-Rosander C. Jonsell G. Agranulocytosis associated with malaria prophylaxis with maloprim Br Med J 286 1983 1244 1245
58. Amos R.S. Bax D.E. Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy Br J Rheumatol 27 1988 465 468
59. Marabani M. Madhok R. Capell H.A. Leucopenia during sulphasalazine treatment for rheumatoid arthritis Ann Rheum Dis 48 1989 505 507
60. Farr M. Tunn E.J. Symmons D.P. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy Br J Rheumatol 28 1989 134 138
61. Fine J.D. Katz S.I. Donahue M.J. Psychiatric reaction to dapsone and sulfapyridine J Am Acad Deramtol 9 1983 274 275
62. Gawkrodger D. Manic depression induced by dapsone in patient with dermatitis herpetiformis Br Med J 299 1989 860
63. Millikan L.E. Harrell E.R. Drug reactions to the sulfones Arch Dermatol 102 1970 220 224
64. Kingham J.G.C. Swain P. Swarbrick E.T. Dapsone and severe hypoalbuminaemia Lancet 2 1979 662 664
65. Young S. Marks J.M. Dapsone and severe hypoalbuminaemia Lancet 1 1979 908 909
66. Cowan R.E. Wright J.T. Dapsone and severe hypoalbuminaemia in dermatitis herpetiformis Br J Dermatol 104 1981 201 204
67. Frey H.M. Gershon A.A. Borkowsky W. Fatal reaction to dapsone during treatment of leprosy Ann Intern Med 94 1981 777 779
68. Grticiute L. Tomatis L. Carcinogenicity of dapsone of mice and rats Int J Cancer 25 1980 123 129
69. Maurus J.N. Hansen's disease in pregnancy Obstet Gynecol 52 1978 22 25
70. Grindulis K.A. McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone Ann Rheum Dis 43 1984 398 401
71. Grindulis K.A. McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on hemoglobin J Rbeumatol 11 1984 776 778
72. Kelley C. Griffiths I.D. Dapsone in rheumatoid arthritis Ann Rheum Dis 40 1981 630
73. Crook P.R. Hortas C. Roberts E.J. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis J Rheumatol 10 1983 805 808
74. Barranco V.P. Dapsone-other indications Int J Dermatol 21 1982 513 514
75. Kelly J.W. Scott J. Sandland M. Vitamin E and dapsone-induced hemolysis Arch Dermatol 120 1984 1582 1584
76. Prussick R. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis Arch Dermatol 128 1992 210 213
77. Coleman M.D. Scott A.K. Breckenridge A.M. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man Br J Clin Pharmacol 30 1990 761 767
78. Coleman M.D. Rhodes L.E. Scott A.K. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients Br J Clin Pharmacol 34 1992 244 249